Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia (clinicaltrials.gov) - Sep 15, 2026 - P3 | N=472 | Recruiting | Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Psychiatry • Schizophrenia
|